SXTP

We rate 60 DEGREES PHARMACEUTICALS, INC. (SXTP) as a Reduce with a composite score of 43.7/100 at a current price of $3.03. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.

The rating is primarily driven by strength in momentum (91th percentile) and stability (31th percentile), which together account for the majority of the composite score. Offsetting weakness in value (4th percentile) and quality (19th percentile) tempers our overall conviction. We assign a No Moat rating (35/100), High uncertainty, and Poor capital allocation.

Key items to watch: sustainability of the current growth rate; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.

60 DEGREES PHARMACEUTICALS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.7/100 places it at rank #3025 in our full 7,333-stock universe. At $5M in market capitalization, 60 DEGREES PHARMACEUTICALS, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.

The near-term outlook is constructive, with revenue growing at 250% and momentum in the 91th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 22th percentile indicates reinvestment patterns that investors should monitor for sustainability.

The margin cascade tells an important story: gross margins of 17% (-25.9pp vs sector) narrow to operating margins of -947% (-948.1pp vs sector) and net margins of -959.4%, yielding a gross-to-net conversion rate of -5788%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.

At a current price of $3.03, 60 DEGREES PHARMACEUTICALS, INC. is trading at a premium to fundamental value. Our value factor score of 4/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.

The stock currently trades at P/B of 0.9x, P/S of 3.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.

We assign a High uncertainty rating to 60 DEGREES PHARMACEUTICALS, INC.. Key risk factors include current negative profitability (net margin -959.4%), below-average price stability (31th percentile), weak quality scores (19th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.

Specific risk factors that inform our assessment include: current negative profitability (net margin -959.4%); below-average price stability (31th percentile); weak quality scores (19th percentile); low beta of -1.45 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 31th percentile and quality factor at the 19th percentile provide a quantitative summary of the overall risk landscape.

Key risk mitigants include: conservative leverage (3% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.

We rate 60 DEGREES PHARMACEUTICALS, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-186.1%), negative profitability, weak asset returns (ROA -120.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — 60 DEGREES PHARMACEUTICALS, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.

Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.

In summary, 60 DEGREES PHARMACEUTICALS, INC. receives a Reduce rating with a composite score of 43.7/100 (rank #3025 of 7,333). Our quantitative framework assigns a No Moat (35/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.

Our analysis does not support a constructive view on 60 DEGREES PHARMACEUTICALS, INC. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.